KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Jazz Pharmaceuticals (JAZZ) Other Gross PP&E Adjustments (2016 - 2026)

Jazz Pharmaceuticals has reported Other Gross PP&E Adjustments over the past 16 years, most recently at $271.7 million for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments rose 15.94% year-over-year to $271.7 million; the TTM value through Dec 2025 reached $271.7 million, up 15.94%, while the annual FY2025 figure was $271.7 million, 15.94% up from the prior year.
  • Other Gross PP&E Adjustments for Q4 2025 was $271.7 million at Jazz Pharmaceuticals, up from $130.4 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $271.7 million in Q4 2025 and troughed at -$221.1 million in Q1 2024.
  • A 5-year average of $27.0 million and a median of $30.2 million in 2021 define the central range for Other Gross PP&E Adjustments.
  • Biggest five-year swings in Other Gross PP&E Adjustments: soared 1522.75% in 2021 and later crashed 145.0% in 2024.
  • Year by year, Other Gross PP&E Adjustments stood at $218.3 million in 2021, then increased by 0.57% to $219.6 million in 2022, then decreased by 13.81% to $189.3 million in 2023, then rose by 23.8% to $234.3 million in 2024, then increased by 15.94% to $271.7 million in 2025.
  • Business Quant data shows Other Gross PP&E Adjustments for JAZZ at $271.7 million in Q4 2025, $130.4 million in Q3 2025, and -$52.1 million in Q2 2025.